Results from the BTCRC-LUN15–029 study showed that administration of PD-1 or PD-L1 inhibitors followed by pembrolizumab plus next-line chemotherapy (docetaxel or gemcitabine) achieved median PFS of 5.1 months, median OS of 24.5 months and ORR of 23.5% among advanced NSCLC patients with a clinical benefit from previous treatment with a PD-1 or PD-L1 inhibitor (47). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.